Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Spermidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | F13A1 | P00488 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | THPO | P40225 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA3 | P07451 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermidine SCHEMBL28472688 | 1.00 | CA12 (0.67) | CA12F13A1CA2CYP1A2ALOX15 | |
| Spermine SCHEMBL364155 | 0.98 | CA12 (0.65) | CA12F13A1CA2CYP1A2ALOX15 | |
| Spermidine SCHEMBL867617 | 0.98 | CA12 (0.70) | CA12F13A1CA2CYP1A2ALOX15 | |
| Spermine SCHEMBL867751 | 0.95 | CA12 (0.68) | CA12F13A1CA2CYP1A2ALOX15 | |
| Spermine SCHEMBL2058654 | 0.95 | CA12 (0.68) | CA12F13A1CA2CYP1A2ALOX15 | |
| Phosphoric Acid SCHEMBL15512587 | 0.93 | CA12 (0.62) | CA12F13A1CA2CYP1A2ALOX15 | |
| Phosphoric Acid SCHEMBL5548350 | 0.86 | CA12 (0.54) | CA12F13A1CA2CYP1A2ALOX15 | |
| Phosphoric Acid SCHEMBL5552800 | 0.86 | CA12 (0.54) | CA12F13A1CA2CYP1A2ALOX15 | |
| Phosphoric Acid SCHEMBL5551700 | 0.86 | CA12 (0.54) | CA12F13A1CA2CYP1A2ALOX15 | |
| Spermidine SCHEMBL6038403 | 0.85 | CA12 (0.58) | CA12F13A1CA2CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012007531-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSING MEDICAL CONDITIONS | MADEO FRANK (AT) | 2012-01-19 | — | — | WO | claimed |
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-01-19 | — | — | US | claimed |
| EP-2398472-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS WITH A POLYAMINE (E.G. SPERMINE, SPERMIDINE) | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-12-28 | — | — | EP | claimed |
| WO-2010081204-A2 | ACTIVATORS OF THE AUTOPHAGIC PATHWAY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-07-22 | — | — | WO | claimed |
| WO-2010081862-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-07-22 | — | — | WO | claimed |
| EP-3727419-B1 | A COMBINATION OF SPERMIDINE AND HIGH PROTEIN COMPOSITION FOR INDUCTION OF AUTOPHAGY | NESTLE SA (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20250177337-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS ON BONE HEALTH | NESTLE SA (CH) | 2025-06-05 | — | — | US | disclosed |
| WO-2025051662-A1 | COMPOSITIONS AND METHODS USING SPERMIDINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2025-03-13 | — | — | WO | disclosed |
| EP-4486316-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS ON BONE HEALTH | Société des Produits Nestlé S.A. (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240415786-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | NESTLE SA (CH) | 2024-12-19 | — | — | US | disclosed |
| CN-118900686-A | Compositions and methods for enhancing musculoskeletal effects of one or more anabolic amino acids on bone health | 雀巢产品有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4422423-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2024-09-04 | — | — | EP | disclosed |
| WO-2014206819-A1 | HYBRID ALGINATE-SILICA BEADS AND METHOD FOR OBTAINING THEM | UNIVERSITE DE NAMUR (BE) | 2014-12-31 | — | — | WO | disclosed |
| WO-2012007531-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSING MEDICAL CONDITIONS | MADEO FRANK (AT) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-01-19 | — | — | US | disclosed |
| EP-2398472-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS WITH A POLYAMINE (E.G. SPERMINE, SPERMIDINE) | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010081204-A3 | POLYAMINE ACTIVATORS ( S PERMINE, S PERMIDINE) OF THE AUTOPHAGIC PATHWAY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010081204-A2 | ACTIVATORS OF THE AUTOPHAGIC PATHWAY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081204-A2 | ACTIVATORS OF THE AUTOPHAGIC PATHWAY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081862-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | BECN1, SQSTM1, ATG7 | CA12 3941/4885F13A1 4081/4885CA2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.